Francis Yao, MD
Associate Clinical Professor, Department of Medicine (Gastroenterology), UCSF
Research Summary
Dr. Francis Yao is a gastroenterologist who serves as medical director of the UCSF Liver Transplant Program. He also directs the UCSF Liver Transplant Outreach and Community Liaison Program.In his research, Yao is interested in liver cancer treatment, particularly as related to liver transplants. He has contributed to important publications in this area. His other research interests include hepatitis B infection and outcomes for patients undergoing liver transplantation.
Selected Publications
- Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver Transplantation for Hepatocellular Carcinoma: Management After the Transplant. Am J Transplant. 2019 Nov 11.
View on PubMed - Mehta N, Dodge JL, Yao FY. REPLY. Hepatology. 2019 Oct; 70(4):1491-1492.
View on PubMed - Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 Aug 02; 2(8):e1910326.
View on PubMed - Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology. 2019 Jul 25.
View on PubMed - Fidelman N, Johanson C, Kohi MP, Kolli KP, Kohlbrenner RM, Lehrman ED, Taylor AG, Kelley RK, Yao FY, Roberts JP, Kerlan RK. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. J Hepatocell Carcinoma. 2019; 6:93-103.
View on PubMed - DesJardin JT, Manicardi M, Svetlichnaya Y, Kolaitis NA, Papolos AI, Selby VN, Zier LS, Klein L, Aras MA, Yao FY, Roberts JP, De Marco T. Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates. Clin Transplant. 2019 Jul; 33(7):e13585.
View on PubMed - Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019 Oct; 70(4):1185-1196.
View on PubMed - Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant. 2019 Aug; 19(8):2210-2218.
View on PubMed - Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken). 2019 Jan; 13(1):20-25.
View on PubMed - Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019 Mar; 69(3):1193-1205.
View on PubMed - Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2019 02; 25(2):207-216.
View on PubMed - Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl. 2019 02; 25(2):228-241.
View on PubMed - Mehta N, Monto A, Yao FY. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology. 2019 03; 156(4):1215-1217.
View on PubMed - Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2019 Jun; 21(6):731-738.
View on PubMed - Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl. 2018 10; 24(10):1346-1356.
View on PubMed - Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl. 2018 09; 24(9):1171-1177.
View on PubMed - Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018 08; 68(2):449-461.
View on PubMed - Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018 05; 102(5):816-822.
View on PubMed - Kotwani P, Saxena V, Dodge JL, Roberts J, Yao F, Hameed B. History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist. Transplantation. 2018 05; 102(5):794-802.
View on PubMed - Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018 03; 24(3):327-329.
View on PubMed